Cancer Biology & Medicine最新文献

{"title":"A retrospective analysis of mature T- and NK-cell lymphomas.","authors":"Junlei Jia, Xiaohui Wang, Zheng Song, Shen Meng, Yue Fei, Jingwei Yu, Xia Liu, Xue Han, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Wenchen Gong, Bin Meng, Xiubao Ren, Xianhuo Wang, Huilai Zhang","doi":"10.20892/j.issn.2095-3941.2023.0464","DOIUrl":"10.20892/j.issn.2095-3941.2023.0464","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"21 3","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10976325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140304999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to Treatment strategies for patients with HER2-positive gastric cancer.","authors":"Feixue Wang, Yi Ba","doi":"10.20892/j.issn.2095-3941.2024.0070","DOIUrl":"10.20892/j.issn.2095-3941.2024.0070","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"21 3","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10976327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing the global cancer burden with gastrointestinal screening: China's 30 years practice.","authors":"Lei Yang, Li Feng, Yong Zhu, Ning Wang, Xinpu Lu, Fanghui Gu, Xiaotian Zhang, Jiafu Ji","doi":"10.20892/j.issn.2095-3941.2023.0516","DOIUrl":"10.20892/j.issn.2095-3941.2023.0516","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"21 3","pages":""},"PeriodicalIF":5.6,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10976323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased <i>LDHB</i> expression in breast tumor cells causes NK cell activation and promotes tumor progression.","authors":"Zhihong Luo, Xiaohua Huang, Xinyi Xu, Kefeng Wei, Yi Zheng, Ke Gong, Wenhua Li","doi":"10.20892/j.issn.2095-3941.2023.0382","DOIUrl":"10.20892/j.issn.2095-3941.2023.0382","url":null,"abstract":"<p><strong>Objective: </strong>Abnormal metabolism is the underlying reason for breast cancer progression. Decreased lactate dehydrogenase B (<i>LDHB</i>) has been detected in breast cancer but the function of <i>LDHB</i> remains unknown.</p><p><strong>Methods: </strong>Western blot was used to analyze <i>LDHB</i> expression in breast cancer cells. The impact of <i>LDHB</i> on tumor cell migration and invasion was determined using Transwell assays, wound healing assays, and a mouse lung metastasis model. Subcutaneous tumor formation, a natural killer (NK) cell cytotoxicity assay, and flow cytometry evaluated NK cell activation. Immunofluorescence and quantitative real-time PCR detected NK cell activation markers. Kaplan-Meier analysis evaluated the effect of immune cell infiltration on prognosis. Single-sample gene set enrichment analysis determined NK cell activation scores. A support vector machine predicted the role of <i>LDHB</i> in NK cell activation.</p><p><strong>Results: </strong>In this study we showed that <i>LDHB</i> inhibits the breast cancer cell metastasis and orchestrates metabolic reprogramming within tumor cells. Our results revealed that <i>LDHB</i>-mediated lactic acid clearance in breast cancer cells triggers NK cell activation within the tumor microenvironment. Our findings, which were confirmed in a murine model, demonstrated that <i>LDHB</i> in tumor cells promotes NK cell activation and ultimately results in the eradication of malignant cells. Clinically, our study further validated that <i>LDHB</i> affects immune cell infiltration and function. Specifically, its expression has been linked to enhanced NK cell-mediated cytotoxicity and improved patient survival. Furthermore, we identified <i>LDHB</i> expression in tumors as an important predictor of NK cell activation, with strong predictive ability in some cancers.</p><p><strong>Conclusions: </strong>Our results suggest that <i>LDHB</i> is a promising target for activating the tumor immune microenvironment in breast cancer, where <i>LDHB</i>-associated lactic acid clearance leads to increased NK cell activity. This study highlights the critical role of <i>LDHB</i> in regulating immune responses and its potential as a therapeutic target for breast cancer.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11208901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial.","authors":"Shuzhen Lai, Peijing Li, Xiaohui Liu, Guihong Liu, Tieming Xie, Xing Zhang, Xiaoxuan Wang, Jing Huang, Yiqiang Tang, Zhigang Liu, Guoping Shen, Chaoming Li, Fangxiao Lu, Lei Wang, Fagui Jiang, Caixing Sun, Yuanyuan Chen, Ming Chen","doi":"10.20892/j.issn.2095-3941.2023.0373","DOIUrl":"10.20892/j.issn.2095-3941.2023.0373","url":null,"abstract":"<p><strong>Objective: </strong>Glioblastomas are highly vascularized malignant tumors. We determined the efficacy and safety of the anti-angiogenic multi-kinase inhibitor, anlotinib, for a newly diagnosed glioblastoma.</p><p><strong>Methods: </strong>This multicenter, single-arm trial (NCT04119674) enrolled 33 treatment-naïve patients with histologically proven glioblastomas between March 2019 and November 2020. Patients underwent treatment with the standard STUPP regimen [fractionated focal irradiation in daily fractions of 1.8-2 Gy given 5 d/w × 6 w (total = 54-60 Gy)] or radiotherapy plus continuous daily temozolomide (TMZ) (75 mg/m² of body surface area/d, 7 d/w from the first to the last day of radiotherapy), followed by 6 cycles of adjuvant TMZ (150-200 mg/m² × 5 d during each 28-d cycle) plus anlotinib (8 mg/d on d 1-14 of each 3-w cycle for 2 cycles during concomitant chemoradiotherapy, 8 maximal cycles as adjuvant therapy, followed by maintenance at 8 mg/d. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and adverse events (AEs).</p><p><strong>Results: </strong>Thirty-three patients received the planned treatment. The median PFS was 10.9 months (95% CI, 9.9-18.7 months) and the 12-month PFS rate was 48.5%. The median OS was 17.4 months (95% CI, 14.5-21.1 months) and the 12-month OS rate was 81.8%. The most common AEs included hypertriglyceridemia [58% (<i>n</i> = 19)], hypoalbuminemia [46% (<i>n</i> = 15)], and hypercholesterolemia [46% (<i>n</i> = 15)] during concurrent chemoradiotherapy and leukopenia [73% (<i>n</i> = 24)], hypertriglyceridemia [67% (<i>n</i> = 22)], and neutropenia [52% (<i>n</i> = 17)] during adjuvant therapy. Five patients discontinued treatment due to AEs. <i>HEG1</i> (HR, 5.6; 95% CI, 1.3-23.7; <i>P</i> = 0.021) and <i>RP1L1</i> alterations (HR, 11.1; 95% CI, 2.2-57.2; <i>P</i> = 0.004) were associated with a significantly shorter PFS.</p><p><strong>Conclusions: </strong>Anlotinib plus the STUPP regimen has promising anti-tumor activity against glioblastoma and manageable toxicity. <i>HEG1</i> and <i>RP1L1</i> alterations might be novel predictive biomarkers of the response to anlotinib.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.6,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11131046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140038785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies.","authors":"Shuangcheng Li, Tianci Wang, Xinghui Xiao, Xiaodong Zheng, Haoyu Sun, Rui Sun, Hongdi Ma, Zhigang Tian, Xiaohu Zheng","doi":"10.20892/j.issn.2095-3941.2023.0341","DOIUrl":"10.20892/j.issn.2095-3941.2023.0341","url":null,"abstract":"<p><strong>Objective: </strong>The human cluster of differentiation (CD)300A, a type-I transmembrane protein with immunoreceptor tyrosine-based inhibitory motifs, was investigated as a potential immune checkpoint for human natural killer (NK) cells targeting hematologic malignancies (HMs).</p><p><strong>Methods: </strong>We implemented a stimulation system involving the CD300A ligand, phosphatidylserine (PS), exposed to the outer surface of malignant cells. Additionally, we utilized CD300A overexpression, a CD300A blocking system, and a xenotransplantation model to evaluate the impact of CD300A on NK cell efficacy against HMs in <i>in vitro</i> and <i>in vivo</i> settings. Furthermore, we explored the association between CD300A and HM progression in patients.</p><p><strong>Results: </strong>Our findings indicated that PS hampers the function of NK cells. Increased CD300A expression inhibited HM lysis by NK cells. CD300A overexpression shortened the survival of HM-xenografted mice by impairing transplanted NK cells. Blocking PS-CD300A signals with antibodies significantly amplified the expression of lysis function-related proteins and effector cytokines in NK cells, thereby augmenting the ability to lyse HMs. Clinically, heightened CD300A expression correlated with shorter survival and an \"exhausted\" phenotype of intratumoral NK cells in patients with HMs or solid tumors.</p><p><strong>Conclusions: </strong>These results propose CD300A as a potential target for invigorating NK cell-based treatments against HMs.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11033714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139995662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of sex on outcomes of liver transplantation for hepatocellular carcinoma: a multicenter cohort study in China.","authors":"Jian Chen, Zhe Yang, Fengqiang Gao, Zhisheng Zhou, Junli Chen, Di Lu, Kai Wang, Meihua Sui, Zhengxin Wang, Wenzhi Guo, Guoyue Lyu, Haizhi Qi, Jinzhen Cai, Jiayin Yang, Shusen Zheng, Xiao Xu","doi":"10.20892/j.issn.2095-3941.2023.0453","DOIUrl":"10.20892/j.issn.2095-3941.2023.0453","url":null,"abstract":"<p><strong>Objective: </strong>Sex-specific differences are observed in various liver diseases, but the influence of sex on the outcomes of hepatocellular carcinoma (HCC) after liver transplantation (LT) remains to be determined. This study is the first Chinese nationwide investigation of the role of sex in post-LT outcomes in patients with HCC.</p><p><strong>Methods: </strong>Data for recipients with HCC registered in the China Liver Transplant Registry between January 2015 and December 2020 were analyzed. The associations between donor, recipient, or donor-recipient transplant patterns by sex and the post-LT outcomes were studied with propensity score matching (PSM). The survival associated with different sex-based donor-recipient transplant patterns was further studied.</p><p><strong>Results: </strong>Among 3,769 patients enrolled in this study, the 1-, 3-, and 5-year overall survival (OS) rates of patients with HCC after LT were 96.1%, 86.4%, and 78.5%, respectively, in female recipients, and 95.8%, 79.0%, and 70.7%, respectively, in male recipients after PSM (<i>P</i> = 0.009). However, the OS was comparable between recipients with female donors and male donors. Multivariate analysis indicated that male recipient sex was a risk factor for post-LT survival (HR = 1.381, <i>P</i> = 0.046). Among the donor-recipient transplant patterns, the male-male donor-recipient transplant pattern was associated with the poorest post-LT survival (<i>P</i> < 0.05).</p><p><strong>Conclusions: </strong>Our findings highlighted that the post-LT outcomes of female recipients were significantly superior to those of male recipients, and the male-male donor-recipient transplant pattern was associated with the poorest post-LT survival. Livers from male donors may provide the most benefit to female recipients. Our results indicate that sex should be considered as a critical factor in organ allocation.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11033715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139995663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current and future trends in whole genome sequencing in cancer.","authors":"Yuki Katsuya","doi":"10.20892/j.issn.2095-3941.2023.0420","DOIUrl":"10.20892/j.issn.2095-3941.2023.0420","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"21 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10875287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139734578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer.","authors":"Qin Tang, Xin Wang, Haixia Wang, Lin Zhong, Dongling Zou","doi":"10.20892/j.issn.2095-3941.2023.0260","DOIUrl":"10.20892/j.issn.2095-3941.2023.0260","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep-learning methods for unveiling large-scale single-cell transcriptomes.","authors":"Xilin Shen, Xiangchun Li","doi":"10.20892/j.issn.2095-3941.2023.0436","DOIUrl":"10.20892/j.issn.2095-3941.2023.0436","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}